RBC Capital Maintains Outperform on Bio-Rad Laboratories, Lowers Price Target to $392
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and lowers the price target from $409 to $392.
RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and lowers the price target from $409 to $392.